Fennec Pharmaceuticals (FENC) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update
May 14, 2020 6:00 AM EDT~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~~ Strengthened its Financial Position Through a Raise of Approximately $32 Million in Net Proceeds ~~ Commercial Readiness Activities are Underway in the U.S. ~
RESEARCH TRIANGLE PARK, N.C., May 14, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the... More
